---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-041133"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2024-10-15T23:59:59+00:00"
generated_at: "2026-05-30T14:36:32.368277+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Oncocyte shareholders approve 1.25M share increase to equity plan

## Summary
- Stockholders approved Amended and Restated 2018 Equity Incentive Plan adding 1,250,000 shares, total pool now 2,300,000 shares.
- Vote: 8,469,172 for, 110,188 against, 8,410 abstained; 64.21% of voting power represented at special meeting on Oct 11, 2024.
- Amendments remove fungible share counting, eliminate share recycling restrictions, and remove one-year vesting minimum.
- Plan authorizes delegation of award grants to executive officers under Board-established limits.

## SEC filing metadata
- accession: 0001493152-24-041133
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2024-10-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315224041133/0001493152-24-041133-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315224041133/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-041133
- JSON: https://secwatch.observer/filing/0001493152-24-041133.json
- Plain text: https://secwatch.observer/filing/0001493152-24-041133.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.